Agios Pharmaceuticals (AGIO) vs Lakefront Biotherapeutics (LKFT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Lakefront Biotherapeutics (LKFT) has outperformed Agios Pharmaceuticals (AGIO) over the past year, losing 14.5% versus a loss of 25.1%. Over five years, AGIO leads with a -31.0% price change compared with -44.9% for LKFT. Lakefront Biotherapeutics is the larger company by market cap ($1.94 billion vs $1.90 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AGIO | LKFT |
|---|---|---|
| Share price | $31.85 | $29.67 |
| Market cap | $1.90B | $1.94B |
| 1-day change | -0.22% | +0.54% |
| YTD return | +17.27% | -9.76% |
| 1-year return | -25.07% | -14.46% |
| 5-year return | -31.03% | -44.86% |
| P/E ratio (TTM) | — | 2.82 |
| EPS (TTM) | $-7.01 | $10.52 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $54.03M | — |
| Revenue growth (YoY) | +48.03% | — |
| Net income (latest FY) | $-412.78M | — |
| Gross margin | 88.26% | — |
| Operating margin | -873.87% | — |
| Net margin | -764.01% | — |
| 52-week high | $46.00 | $36.24 |
| 52-week low | $22.24 | $25.68 |
| Distance from 52-week high | -30.76% | -18.13% |
| Analyst consensus | buy | hold |
| Avg. price target upside | +44.43% | +1.72% |
| Average volume | 1.08M | 273.30K |
| Shares outstanding | 59.70M | 65.48M |
| Employees | 539 | 196 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- LKFT has outperformed AGIO by 10.6 percentage points over the past year.
About Agios Pharmaceuticals
AGIO stock →Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency.
Health Care · Biotechnology: Pharmaceutical Preparations · 539 employees
About Lakefront Biotherapeutics
LKFT stock →Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in a phase 1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.
Health Care · Biotechnology: Pharmaceutical Preparations · 196 employees
AGIO vs LKFT FAQ
Which is bigger, Agios Pharmaceuticals or Lakefront Biotherapeutics?
Lakefront Biotherapeutics (LKFT) is larger, with a market capitalization of $1.94B compared with $1.90B for Agios Pharmaceuticals (AGIO).
Which stock has performed better over the past year, AGIO or LKFT?
LKFT returned -14.46% over the past 12 months, compared with -25.07% for AGIO (price return, excluding dividends). Past performance does not predict future results.
Are Agios Pharmaceuticals and Lakefront Biotherapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.